LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "fgfr alterations" as a keyword



LGG-60. DISTRIBUTION AND CLINICAL SIGNIFICANCE OF FGFR ALTERATIONS IN PEDIATRIC AND AYA GLIOMAS

Sign Up to like & get
recommendations! Published in 2024 at "Neuro-Oncology"

DOI: 10.1093/neuonc/noae064.449

Abstract: Abstract Fibroblast growth factor receptor (FGFR) alterations are prevalent in human cancers. In a large Canadian population-based cohort, encompassing over 1,300 pediatric and Adolescent and young adult (AYA) gliomas, FGFR mutations occurred in 10% of… read more here.

Keywords: fgfr alterations; gliomas; grade gliomas; aya gliomas ... See more keywords

BIOM-79. TARGETING FGFR ALTERATIONS IN GLIOMAS: A SINGLE-INSTITUTION CASE SERIES

Sign Up to like & get
recommendations! Published in 2025 at "Neuro-Oncology"

DOI: 10.1093/neuonc/noaf201.0167

Abstract: Fibroblast growth factor receptor (FGFR) alterations are a potentially actionable target in various cancers, including glioblastoma (GBM). FGFR inhibitors have shown variable efficacy in GBM to date. We present a single-institution experience utilizing FGFR inhibitors… read more here.

Keywords: fgfr alterations; fgfr inhibitors; single institution; fusion ... See more keywords

Re: Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Urology"

DOI: 10.1097/01.ju.0000614704.30826.9b

Abstract: available at http://www.ncbi.nlm.nih.gov/pubmed/31340094 Editorial Comment: This open-label phase 2 study examined the impact of oral erdafitinib, a tyrosine kinase inhibitor of fibroblast growth factor receptors (FGFRs) 1 through 4, in patients with locally advanced/unresectable or… read more here.

Keywords: locally advanced; carcinoma; fgfr alterations; urothelial carcinoma ... See more keywords

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

Sign Up to like & get
recommendations! Published in 2022 at "Clinical Cancer Research"

DOI: 10.1158/1078-0432.ccr-21-2664

Abstract: Abstract Purpose: FGFR genomic alterations (amplification, mutations, and/or fusions) occur in ∼8% of gliomas, particularly FGFR1 and FGFR3. We conducted a multicenter open-label, single-arm, phase II study of a selective FGFR1–3 inhibitor, infigratinib (BGJ398), in… read more here.

Keywords: fgfr alterations; recurrent gliomas; patients recurrent; phase study ... See more keywords

TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid malignancies with FGFR alterations identified by circulating tumor DNA.

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2019.37.15_suppl.tps3156

Abstract: TPS3156 Background: Approximately 7% of advanced solid malignancies have FGFR gene alterations. However, standard treatment for FGFR-altered malignancies has not been established. Moreover, circulating tumor DNA (ctDNA) analysis has a potential to accurately identify FGFR… read more here.

Keywords: fgfr alterations; advanced solid; malignancies fgfr; tas 120 ... See more keywords

Incidence and potential prognostic implications of fibroblast growth factor receptor gene alterations and coexisting mutations in colorectal cancer.

Sign Up to like & get
recommendations! Published in 2024 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2024.42.16_suppl.e15558

Abstract: e15558 Background: The fibroblast growth factor receptor (FGFR) family comprises four tyrosine kinase receptors (FGFR1-4). FGFR1 amplification (6.3%) as well as overexpression of FGFR1 (10.1%), FGFR2 (5.5%) and FGFR3 (16.2%) have been demonstrated in primary… read more here.

Keywords: colorectal cancer; fgfr alterations; fibroblast growth; factor receptor ... See more keywords

Comprehensive landscape of FGFR variations and prognosis revelance in colorectal cancer from circulating tumor DNA and tissue gene analyses in 2083 patients.

Sign Up to like & get
recommendations! Published in 2025 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2025.43.4_suppl.278

Abstract: 278 Background: FGFR genomic alterations have been identified, and several FGFR inhibitors are approved for various malignancies, including bladder and cholangiocarcinoma. However, limited studies have shown FGFR alterations and their prognostic impact in colorectal cancer… read more here.

Keywords: fgfr alterations; pfs; colorectal cancer; fgfr ... See more keywords